Immune-mediated pathology in Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

Immune-mediated pathology in Duchenne muscular dystrophy

Published:2015-08-05 Issue:299 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Rosenberg Amy S.¹,Puig Montserrat¹,Nagaraju Kanneboyina²,Hoffman Eric P.²,Villalta S. Armando³,Rao V. Ashutosh¹,Wakefield Lalage M.⁴,Woodcock Janet¹

Affiliation:

1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Building 71/2238, Silver Spring, MD 20993, USA.

2. Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC 20010, USA.

3. Department of Physiology and Biophysics, Institute for Immunology, University of California, Irvine, Irvine, CA 92697, USA.

4. Laboratory of Cancer Biology and Genetics, National Cancer Institute, Building 37, Room 4032A, Bethesda, MD 20892, USA.

Abstract

Immunopathology contributes to the destruction and fibrosis of muscle in Duchenne muscular dystrophy, reducing the efficacy of dystrophin-replacement therapies.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference109 articles.

1. The Paradox of Muscle Hypertrophy in Muscular Dystrophy

2. General recommendations on immunization—Recommendations of the Advisory Committee on Immunization Practices (ACIP);National Center for Immunization and Respiratory Diseases;MMWR Recomm. Rep.,2011

3. The inflammasome: a danger sensing complex triggering innate immunity

4. Extracellular matrix remodeling and its contribution to protective adaptation following lengthening contractions in human muscle

5. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insight into the Role of Gut Microbiota in Duchenne Muscular Dystrophy;The American Journal of Pathology;2024-02

2. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice;PLOS ONE;2024-01-25

3. How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?;Proteomes;2024-01-16

4. Retention of stress susceptibility in the mdx mouse model of Duchenne muscular dystrophy after PGC-1α overexpression or ablation of IDO1 or CD38;Human Molecular Genetics;2024-01-05

5. Identifying hub genes and dysregulated pathways in Duchenne muscular dystrophy;International Journal of Neuroscience;2024-01-05